Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice

Immunology

Volumn 122, Issue 4, 2007, Pages 496-502

  Lu, Xinya ^a,b   Chen, Yao ^a,b   Bai, Bingke ^a,b   Hu, Hui ^a,b   Tao, Ling ^a,b   Yang, Jihong ^b,c   Chen, Jianjun ^a,b   Chen, Ze ^a   Hu, Zhihong ^a   Wang, Hanzhong ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Hunzhong Normal University ^*  (China)

Author keywords

Baculovirus expression vector system; Coronavirus; Immune response; Severe acute respiratory syndrome; Vaccine; Virus like particles

Indexed keywords

M PROTEIN; PROTEIN VP3; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VIRUS ANTIBODY; VITRONECTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; ELECTRON MICROSCOPY; LEUKEMIA VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS LIKE AGENT;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON TYPE II; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL VACCINES;

EID: 35948940526     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2007.02676.x     Document Type: Article

References (29)

1. Ksiazek TG, Erdman D, Goldsmith CS et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003 348: 1953 66.
2. Drosten C, Gunther S, Preiser W et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003 348: 1967 76.
3. Peiris JS, Lai ST, Poon LL et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003 361: 1319 25.
4. Marra MA, Jones SJ, Astell CR et al. The genome sequence of the SARS-associated coronavirus. Science 2003 300: 1399 404.
5. Rota PA, Oberste MS, Monroe SS et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003 300: 1394 9.
6. Bonavia A, Zelus BD, Wentworth DE, Talbot PJ, Holmes KV. Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E. J Virol 2003 77: 2530 8.
7. Kubo H, Yamada YK, Taguchi F. Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein. J Virol 1994 68: 5403 10.
8. Babcock GJ, Esshaki DJ, Thomas WD Jr., Ambrosino DM. Amino acids 270-510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 2004 78: 4552 60.
9. Li W, Moore MJ, Vasilieva N et al. Angiostensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003 426: 450 4.
10. He Y, Li J, Heck S, Lustigman S, Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol 2006 80: 5757 67.
11. Du L, He Y, Wang Y et al. Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies. Implication for developing SARS vaccines. Virology 2006 353: 6 16.
12. de Haan CA, Kuo L, Masters PS, Vennema H, Rottier PJ. Coronavirus particle assembly: primary structure requirements of the membrane protein. J Virol 1998: 72: 6838 50.
13. Surjit M, Liu B, Kumar P, Chow VT, Lal SK. The nucleocapsid protein of the SARS coronavirus is capable of self association through a C-terminal 209 amino acid interaction domain. Biochem Biophys Res Comms 2004 317: 1030 6.
14. Kuo L, Masters PS. The small envelope protein E is not essential for murine coronavirus replication. J Virol 2003: 77: 4597 608.
15. Corse E, CE. Machamer. Infectious bronchitis virus E protein is targeted to the Golgi complex and directs release of virus-like particles. J Virol 2000 74: 4319 26.
16. Baudoux P, Carrat C, Besnardeau L, Charley B, Laude H. Coronavirus pseudoparticles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. J Virol 1998 72: 8636 43.
17. Gibco BRL. BAC-TO-BAC Baculovirus Expression Systems. Carlsbad, CA: GibcoBRL, 2002.
18. Giroglou T, Cinatl J Jr., Rabenau H, Drosten C, Schwalbe H, Doerr HW, von Laer D. Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol 2004 78: 9007 15.
19. Spruth M, Kistner O, Savidis-Dacho H et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 2006 24: 652 61.
20. Zhou Z, Post P, Chubet R, Holtz K, McPherson C, Petric M, Cox M. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS CoV) neutralizing antibodies in mice. Vaccine 2006 24: 3624 31.
21. Evans TG, Bonnez W, Rose RC. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001 183: 1485 93.
22. Roy P, Bishop DH, LeBlois H, Erasmus BJ. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection. Vaccine 1994 12: 805 11.
23. Jeong SH, Qiao M, Nascimbeni M, Hu Z, Rehermann B, Murthy K, Liang TJ. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol 2004 78: 6995 7003.
24. O'Neal CM, Clements JD, Estes MK, Conner ME. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge. J Virol 1998 72: 3390 3.
25. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. Influenza virus-like particles comprised of the HA,NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005 23: 5751 9.
26. Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005 18: 244 51.
27. Huang Y, Yang ZY, Kong WP, Nabel GJ. Generation of synthetic severe acute respiratory syndrome coronavirus pseudoparticles: implications for assembly and vaccine production. J Virol 2004 78: 12557 65.
28. Ho Y, Lin PH, Liu CY, Lee SP, Chao YC. Assembly of human severe acute respiratory syndrome coronavirus-like particles. Biochem Biophys Res Comms 2004 318: 833 8.
29. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002 347: 1645 51.